JBCHEPHARM - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 4.1
| Stock Code | JBCHEPHARM | Market Cap | 35,407 Cr. | Current Price | 2,204 ₹ | High / Low | 2,285 ₹ |
| Stock P/E | 51.0 | Book Value | 251 ₹ | Dividend Yield | 0.70 % | ROCE | 25.2 % |
| ROE | 18.7 % | Face Value | 1.00 ₹ | DMA 50 | 2,084 ₹ | DMA 200 | 1,919 ₹ |
| Chg in FII Hold | 1.45 % | Chg in DII Hold | -1.97 % | PAT Qtr | 116 Cr. | PAT Prev Qtr | 179 Cr. |
| RSI | 61.8 | MACD | 40.8 | Volume | 1,71,556 | Avg Vol 1Wk | 3,02,706 |
| Low price | 1,603 ₹ | High price | 2,285 ₹ | PEG Ratio | 2.36 | Debt to equity | 0.00 |
| 52w Index | 88.1 % | Qtr Profit Var | -22.6 % | EPS | 42.0 ₹ | Industry PE | 31.6 |
📊 Chart & Trend Analysis:
JBCHEPHARM is trading above both its 50 DMA (₹2,084) and 200 DMA (₹1,919), confirming strong bullish momentum. RSI at 61.8 indicates mildly overbought conditions. MACD at 40.8 shows strong positive crossover. Bollinger Bands suggest price is near the upper band, with support around ₹2,080.
📈 Momentum Signals:
- Short-term momentum is positive, though volume (1.71L) is below weekly average (3.02L), showing weaker participation.
- Support zone: ₹2,080 – ₹2,100.
- Resistance zone: ₹2,250 – ₹2,285.
- Break above ₹2,285 could trigger a rally toward new highs; failure to hold ₹2,080 may lead to consolidation.
🔎 Trend Status:
Currently trending upward with bullish undertones. Sustained buying above ₹2,250 will confirm continuation of the uptrend.
---
Positive
✔ Strong ROCE (25.2%) and ROE (18.7%) highlight efficient capital use.
✔ EPS at ₹42 supports valuation strength.
✔ Debt-free balance sheet (0.00 debt-to-equity).
✔ FII holdings increased (+1.45%), showing foreign investor confidence.
✔ 52-week performance at +88.1% indicates strong momentum.
Limitation
⚠ High P/E ratio (51.0) vs industry PE (31.6) suggests premium valuation.
⚠ PEG ratio at 2.36 indicates overvaluation relative to growth.
⚠ Dividend yield modest at 0.70%.
⚠ Volume participation remains weak compared to average.
Company Negative News
📉 Sequential PAT decline (₹179 Cr → ₹116 Cr).
📉 Domestic institutional holdings decreased (-1.97%).
Company Positive News
📢 Strong FII inflows.
📢 Technical breakout above both DMA levels.
📢 Sectoral strength in pharma supports long-term growth.
Industry
🌐 Industry PE at 31.6 vs JBCHEPHARM’s 51.0 — premium valuation.
🌐 Pharma sector outlook remains positive with defensive demand and steady growth.
Conclusion
JBCHEPHARM is trending upward with bullish signals from DMA, RSI, and MACD. Entry near ₹2,080–₹2,100 offers favorable risk-reward, with exit targets around ₹2,250–₹2,285. Fundamentals remain strong, though valuation is stretched. Traders can ride momentum with strict stop-loss discipline, while long-term investors should be cautious of overvaluation.
Would you like me to expand this into a swing trade roadmap with layered targets, or refine it into a sector benchmarking overlay comparing JBCHEPHARM against peers like Sun Pharma and Cipla?